REMS Drug Access: What Sponsors and CROs Need to Know Before Procurement
Some drugs can’t be bought freely. Their safety risks need extra controls. The FDA calls these controls REMS.
For sponsors and CROs, this matters greatly. REMS shapes who can buy. It shapes who can store and ship. It shapes timelines and trial budgets.
This guide explains REMS drug access clearly. It’s written for procurement and sourcing teams.
What Is a REMS Drug?
REMS means Risk Evaluation and Mitigation Strategy. It sits under Section 505-1 of the FD&C Act. It was added by the 2007 FDAAA. FDA requires it for serious safety concerns. Standard labeling alone isn’t enough there.
A REMS may include these core tools:
↳ Medication Guide for patients
↳ Communication Plan for prescribers
↳ Elements to Assure Safe Use (ETASU)
ETASU is where procurement gets complex. It can require prescriber or pharmacy certification. It can restrict dispensing settings. It can mandate monitoring or registry enrollment.
How Many REMS Programs Are Active?
Early 2025 data showed 73 active REMS. Of those, 69 carried ETASU. By June 2025, about 70 remained active. Of these, 64 had ETASU.
The number keeps moving. FDA updates its REMS dashboard weekly. Check it before every sourcing request.
The REMS Landscape Is Shifting
REMS rules are not fixed. FDA reviews them over time. Recent changes show a clear direction. Burden eases where labeling is sufficient.
↳ Clozapine REMS was removed June 13, 2025.
↳ CD19 and BCMA CAR-T REMS ended. That change came on 27 June 2025.
↳ iPLEDGE changes were approved February 9, 2026. Implementation moved to November 15, 2026.
↳ Nexplanon now carries a new REMS. Wholesalers must register with the program. They supply only certified pharmacies and providers.
So one program eases. Another adds new steps. Your sourcing plan must track both.
Why REMS Complicates Clinical Trial Procurement
Trials often need REMS drugs as comparators. Generic developers need them as RLDs. Bioequivalence studies usually compare against the RLD. Distribution limits can restrict that access.
Common friction points include:
↳ Limited distribution networks
↳ Certified pharmacy dispensing rules
↳ Prescriber enrollment before release
↳ Patient registry duties during trials
↳ Documentation for every unit shipped
Each point adds time. Each point adds compliance exposure. One missed step can delay release.
The CREATES Act: A Pathway for Developers
Sample access disputes led to reform. The CREATES Act was signed in December 2019. It helps developers obtain needed product samples. Generic, 505(b)(2) and biosimilar developers qualify.
For ETASU products, one step comes first. Developers need a Covered Product Authorization. FDA issues this authorization. Supplying samples under it won’t violate REMS.
Non-ETASU products don’t need this step. Know which applies before you begin.
A Pre-Procurement Checklist for Sponsors and CROs
Before requesting any REMS drug:
↳ Confirm current status on REMS@FDA
↳ Identify every ETASU element involved
↳ Check for a shared system REMS
↳ Map certified distributors and pharmacies
↳ Confirm site and investigator certification
↳ Assess whether a CPA is required
↳ Plan cold chain and custody records
↳ Build buffer time into study start
↳ Align paperwork with DSCSA traceability
This checklist saves weeks later. It also protects audit readiness.
Beyond the US: Global Comparator Sourcing
REMS is a US framework. Other regions use different tools. The EU uses additional risk minimisation measures. These are known as aRMMs. Global trials often face both systems. Sourcing must respect each market’s rules.
How NewLife Medicals Supports REMS Drug Access
Restricted drugs need careful partners. We’ve supplied the US market since 2016. We hold wholesale drug licenses. Our 3PL facility sits in North Carolina. Our EU base sits in Dublin, Ireland. Our network spans 35+ countries.
We support sponsors and CROs through:
↳ REMS status and feasibility checks
↳ Sourcing through authorised channels only
↳ Complete documentation and chain of custody
↳ Temperature-controlled global logistics
↳ Comparator and RLD supply for trials
We don’t work around REMS. We help you work within it. That protects patients. It protects your trial too.
Final Thoughts
REMS will keep evolving. Some programs will ease. Others will add new layers. Early planning keeps trials on schedule. The right partner keeps them compliant.
Planning a trial with a REMS drug? Talk to our sourcing team today. Start at newlifemedicals.com.
Frequently Asked Questions
It’s a drug with an FDA safety program. The program goes beyond standard labeling. It manages serious, specific risks.
Yes, through authorised channels. Every ETASU requirement must be met. Certification and documentation come first.
ETASU means Elements to Assure Safe Use. It covers certification and dispensing controls. It may include monitoring or registries.
It’s an FDA authorization under CREATES. It applies to ETASU products. It supports sample access for developers.
Use REMS@FDA and the REMS Public Dashboard. Both come directly from FDA.
